B
Batai Medical develops biotech solutions for the Chinese healthcare market.
$280KSeries D
Investor undisclosed
A $300K Series D in 2026 is a red flag—either this is a down round or the company is in serious trouble. If Batai is still fundraising at this stage with this amount, it suggests the China biotech market is either consolidating hard or this company lost momentum with earlier backers. If you're building biotech in Asia, watch whether Chinese VCs are rotating away from early-stage biotech entirely.